Utility-based optimization of phase II/III programs.

about

Optimizing Trial Designs for Targeted Therapies Bayesian Phase II optimization for time-to-event data based on historical information.A decision theoretical modeling for Phase III investments and drug licensing.

P2860

Q28554393-0B2DFC1B-4187-4B80-8ECE-463FB0D0B9FA Q47238385-6296F774-E5BF-4A37-A411-118439BD04F0 Q47683946-43555693-DEFB-4EA8-83BF-9D1F0D297E9A

P2860

Utility-based optimization of phase II/III programs.

Item

http://www.wikidata.org/entity/Q40643754

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Utility-based optimization of phase II/III programs.

@en

type

Item

label

Utility-based optimization of phase II/III programs.

@en

prefLabel

Utility-based optimization of phase II/III programs.

@en

P1476

Utility-based optimization of phase II/III programs.

@en

P2093

Armin Schüler

http://www.w3.org/2001/XMLSchema#string

Heiko Götte

http://www.w3.org/2001/XMLSchema#string

Marietta Kirchner

http://www.w3.org/2001/XMLSchema#string

P2860

Estimating the cost of new drug development: is it really 802 million dollars?

Adapting the sample size planning of a phase III trial based on phase II data.

Adapting by calibration the sample size of a phase III trial on the basis of phase II data.

Assessing the success probability of a Phase III clinical trial based on Phase II data.

Bayesian optimal design for phase II screening trials

A mathematical model for maximizing the value of phase 3 drug development portfolios incorporating budget constraints and risk.

A predictive approach to selecting the size of a clinical trial, based on subjective clinical opinion.

Accounting for variability in sample size estimation with applications to nonadherence and estimation of variance and effect size.

A Bayesian approach for incorporating economic factors in sample size design for clinical trials of individual drugs and portfolios of drugs.

Bayesian sample size determination in non-sequential clinical trials: Statistical aspects and some regulatory considerations.

P304

305-316

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/SIM.6624

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Meinhard Kieser

P577

2015-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26256550

http://www.w3.org/2001/XMLSchema#string

Utility-based optimization of phase II/III programs.

about

P2860

P2860

Utility-based optimization of phase II/III programs.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698